Abstract: The present invention relates to a pharmaceutical capsule composition comprising eltrombopag olamine or a pharmaceutically acceptable salt thereof for use in the treatment of thrombocytopenia. Furthermore, the present invention relates to an improved, simple, rapid, cost-effective, time-saving and industrially available method of preparing the capsule composition comprising eltrombopag olamine.

Abstract: Pharmaceutical compositions comprising flurbiprofen or a pharmaceutically acceptable salt thereof in combination with at least one 5-HT1-receptor agonist or a pharmaceutically acceptable salt thereof. In this invention, the composition comprising flurbiprofen and 5-HT1-receptor agonists are used for treating or preventing migraine headache. Furthermore, in this invention, in order to overcome incompatibility and stability problems of these active agents, some solutions were offered, and stable pharmaceutical compositions have been developed.

Abstract: The present invention relates to a natural sweetening composition comprising Luo Han Guo concentrate in an amount of 0.1 to 95% by weight and use in beverage, food, pharmaceutical, oral, dietetic, veterinary or tobacco products thereof.

Abstract: The present invention relates to improvements made in the blister advancement mechanism of dry powder inhaler devices. A dry powder inhaler device mechanism comprising an actuator plate and a transmission wheel is provided.

Abstract: This invention is a novel pharmaceutical composition comprising dabigatran or a pharmaceutically acceptable salt thereof in combination with a proton pump inhibitor for use in the antithrombotic treatment with preventing or reducing the risk of a gastrointestinal disorder.

Abstract: The invention relates to pharmaceutical powder compositions administered by means of inhalers. More particularly, it relates to pharmaceutical powder compositions having the content uniformity and the desired stability used in inhaler devices.

Abstract: The invention relates to pharmaceutical powder compositions administered by means of inhalers. More particularly, it relates to pharmaceutical powder compositions having the content uniformity and the desired stability used in inhaler devices.

Abstract: The present invention relates to a pharmaceutical capsule composition comprising fingolimod or its pharmaceutically acceptable salts thereof, a cellulose derivatives excipient and at least one pharmaceutically acceptable excipient.

Abstract: This invention is about a blister which is an integral component of a dry powder inhaler and is structured from a base sheet and a lid sheet comprising at least two layers made from polymeric materials and flat aluminium foil, wherein the cavity that is used for storing the inhalable formulation is in the volume range of 5 to 19.8 mm3 and the cavity is filled up to 25-100%.

Abstract: The present invention relates to a natural sweetening composition comprising Luo Han Guo concentrate in an amount of 0.1 to 95% by weight and use in beverage, food, pharmaceutical, oral, dietetic, veterinary or tobacco products thereof.

Abstract: The present invention relates to a dry powder inhaler device comprising a body having a guide surface formed on an inner surface thereof, a trigger having a socket with a shape complementing the guide surface, and a spring, characterized by comprising at least one retaining element (8) positioned on the inner surface (1) of the body diagonally across the spring (6) to enable the trigger (5) to perform a stable axial displacement and a mechanism check or quality control to be made as one of the parts of the device (7) body is not closed or assembled yet.

Abstract: The present invention relates to a natural sweetening composition comprising apple concentrate having a median particle size (d50) greater than 100 ?m and Luo Han Guo concentrate having a median particle size (d50) greater than 1 ?m and use in beverage, food, pharmaceutical, oral, dietetic, veterinary or tobacco products thereof.

Abstract: The present invention relates to a natural sweetening composition comprising Luo Han Guo concentrate having a median particle size (d50) greater than 1 ?m and use in beverage, food, pharmaceutical, oral, dietetic, veterinary or tobacco products thereof.

Abstract: The present invention relates to a novel process used for the preparation of dry powder formulations for inhalation.

Abstract: The present invention relates to stable oral topical aqueous pharmaceutical compositions comprising flurbiprofen or pharmaceutically acceptable salts thereof and dexpanthenol or pharmaceutically acceptable salts thereof. Furthermore the present invention also relates to stable oral topical aqueous pharmaceutical compositions comprising flurbiprofen or pharmaceutically acceptable salts thereof and dexpanthenol or pharmaceutically acceptable salts thereof and chlorhexidine or pharmaceutically acceptable salts thereof. More particularly, the present invention relates to stable oral topical aqueous pharmaceutical compositions of these combinations having desired levels of solubility, enhanced taste and absorption from mucosal surface, wherein the pH of the solution is between 6 and 7.

Abstract: The present invention relates to a pharmaceutical formulation comprising an immediate release phase comprising an effective amount of flurbiprofen and a controlled release phase comprising an effective amount of tramadol and pharmaceutically acceptable excipients.

Abstract: The present invention relates to a pharmaceutical composition comprising flurbiprofen and tramadol or pharmaceutically acceptable salts thereof and at least one pharmaceutically acceptable excipient.

Abstract: The present invention relates to a pharmaceutical formulation comprising therapeutically effective amount of vildagliptin or pharmaceutically acceptable salt thereof and a diluent. Particularly, the ratio of vildagliptin to diluent is in the range of 0.04 to 0.24 (w/w).

Abstract: The present invention relates to a novel process used for the preparation of dry powder formulations for inhalation.

Abstract: A pharmaceutical combination comprising sitagliptin or a pharmaceutically acceptable salt thereof in combination with a sulfonylurea.